ModifiedUnitedHealthcarePolicy CSIGSNE.D

Genetic Testing for Neuromuscular Disorders (for Nebraska Only)

This document discusses clinical utility, diagnostic yield, and applications of NGS panels and other genetic testing approaches for various neuromuscular disorders (NMDs) including myopathies, metabolic myopathies, glycogen storage diseases, fatty acid oxidation disorders, ataxias, and inherited peripheral neuropathies; it is intended for clinicians and payers evaluating testing strategies.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neuromuscular Disorders (for Nebraska Only)

Policy CodePolicy CSIGSNE.D

Change TypeCoverage rationale addedsupporting sections revised

Effective DateOct 1, 2024

Next Review Date

Key ActionDocument prior targeted testing and clinical findings when requesting broader NGS panels or WES/WGS to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Added language to clarify multi-gene comprehensive neuromuscular disease test panels targeting multiple conditions (e.g., muscular dystrophy and mitochondrial disease) are unproven and not medically necessary.

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

43.3%diagnostic rate (MotorPlex)

30%diagnostic yield (GSD panel)

46%molecular diagnosis rate (ataxia)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

yield (targeted myopathy panel)

multi-gene panels unprovenpolicy stance

Coverage Criteria and Rationale

General coverage criteria for genetic testing in NMD

Covered when ALL of the following are met (inferred from clinical utility studies):

Clinical indication and prior evaluation: Clinical phenotype consistent with a neuromuscular disorder (e.g., limb-girdle muscular dystrophy, congenital myopathy, metabolic myopathy including Pompe, hereditary ataxia, or inherited peripheral neuropathy) AND appropriate prior diagnostic testing has been performed when indicated (for example: enzymatic assays such as GAA activity for Pompe, forearm exercise testing for glycogen defects, mass spectrometry acylcarnitine for fatty acid oxidation disorders, electrodiagnostic testing including EMG/nerve conduction studies, and CNV evaluation such as PMP22 duplication/deletion).

See clinical utility studies and diagnostic cohorts supporting NGS panel use when phenotype is non-specific.

Testing approach: Use of targeted NGS multi-gene panels is appropriate when the phenotype is genetically heterogeneous or non-specific; an algorithmic approach (targeted CNV/expansion testing or single-gene testing first when a specific phenotype is suggested, then panel testing, then reflex to WES/WGS if nondiagnostic) is acceptable.

Supported by MotorPlex, Lantern/Levesque, and CMT panel studies.

Medical necessity criteria for genetic testing

Covered when testing is ordered consistent with clinical guidelines and a phenotype-driven approach:

Initial requirements: Clinical phenotype, family history, and electrodiagnostic features support a hereditary neuromuscular disorder, and documentation demonstrates consideration or exclusion of common high-yield tests (e.g., PMP22 duplication/deletion, GJB1, MFN2) where relevant.

A stepwise phenotype-directed approach is recommended by AAN/AANEM guidance.

Test selection: Selection of targeted multi-gene NGS panels (including CNV analysis) is covered when the phenotype implicates multiple genes or prior single-gene testing is non-diagnostic; WES/WGS may be considered if panels are nondiagnostic or not feasible given coverage limitations.

Cohort studies report higher diagnostic yields for panels versus sequential single-gene testing in CMD, LGMD, and IPN.

Coverage criteria and diagnostic workflow

Coverage supported when testing aligns with specialty society phenotype-directed recommendations and diagnostic workflow:

Phenotype-directed testing before broad testing: Perform a focused clinical evaluation (pattern of weakness, EMG, muscle biopsy findings, CK, and cardiopulmonary assessment) to narrow the differential; when a specific phenotype points to a single gene or small set of genes, obtain targeted single-gene or small-panel testing first.

AAN/AANEM recommend phenotype- and biopsy-directed testing to guide efficient genetic testing.

Use of targeted NGS panels: When phenotype is heterogeneous or initial targeted testing is nondiagnostic, targeted NGS panels covering relevant neuromuscular genes (with CNV analysis) are reasonable first-tier or next-step tests.

Supported by multiple diagnostic cohort studies showing substantial yields for targeted panels.

Muscle biopsy and tissue-based testing: If genetic testing is nondiagnostic or phenotype remains unclear, perform muscle biopsy with immunohistochemistry/biochemical testing and consider tissue-based mtDNA testing when blood testing is negative or heteroplasmy is suspected.

Coverage rationale and testing recommendations

Key coverage stances and recommended testing approach from this section:

Preferred mitochondrial testing approach: When nuclear gene testing is considered for individuals with likely primary mitochondrial disease, use NGS methodologies with complete coverage of known mitochondrial disease genes rather than single-gene testing; if panels are nondiagnostic, consider WES.

MMS guidance: avoid single-gene testing because of phenotypic overlap; consider WES if panels do not identify a mutation.

Specimen and testing considerations: When a tissue specimen is obtained for mitochondrial studies, perform mtDNA copy-number testing via real-time quantitative PCR when depletion is a concern; recognize mtDNA proliferation is nonspecific and consider alternate tissues for heteroplasmy assessment.

MMS recommends tissue testing and mtDNA copy-number analysis because depletion may not be detected in blood.

Not medically necessary test type: Multi-gene comprehensive neuromuscular disease test panels that target multiple distinct conditions (for example, combining muscular dystrophy and mitochondrial disease gene sets into a single broad panel) are considered unproven and not medically necessary.

No specific absolute exclusions are listed for genetic testing in this excerpt; however, the policy emphasizes that testing ordered without prior appropriate diagnostic evaluation may be unsupported. Documented biochemical or enzymatic testing (for example, forearm exercise testing for suspected glycogen storage disease or GAA enzyme assay when Pompe is suspected) and other relevant clinical investigations should be performed and recorded when indicated to narrow the differential diagnosis before broad genetic testing is pursued.

Routine genetic testing is not supported for individuals with cryptogenic polyneuropathy who do not demonstrate a classical hereditary neuropathy phenotype. Initial testing should be guided by clinical phenotype, inheritance pattern, and electrodiagnostic features and should focus on common high-yield abnormalities; absence of a hereditary phenotype or appropriate electrodiagnostic findings may make broad genetic testing inappropriate.

When mitochondrial disease is suspected, mtDNA genome NGS (massively parallel sequencing of the mitochondrial genome) is the preferred methodology per Mitochondrial Medicine Society guidance. Reliance on limited mtDNA mutation panels alone when full mtDNA genome NGS is indicated is discouraged because targeted mutation panels can miss heteroplasmic or tissue-specific variants.

The policy clarifies that multi-gene comprehensive neuromuscular disease test panels that target multiple conditions (for example, panels that simultaneously target muscular dystrophy and mitochondrial disease) are considered unproven. Such multi-condition panels are categorized as not medically necessary in this revision and may not be covered.

Ordering broad genetic testing without first completing recommended preliminary evaluations (clinical examination, targeted laboratory and metabolic testing, imaging, and where appropriate electrophysiologic studies) is discouraged. Studies and guideline authors recommend stepwise selection of tests—use clinical and routine laboratory/imaging results to direct specific genetic testing choices rather than reflexive broad genomic testing.

Genetic testing ordered without documentation that the individual exhibits a hereditary phenotype or without appropriate clinical or electrodiagnostic indicators may be considered not medically necessary. The policy requires documentation of phenotype, inheritance considerations, and which high-yield common abnormalities have been assessed to justify genetic testing.

Reiterating policy stance: multi-gene panels that target multiple neuromuscular conditions (e.g., combined muscular dystrophy and mitochondrial disease panels) are classified as not medically necessary in this policy update and therefore are not supported for routine coverage.

Indications Considered Medically Necessary

Suspected neuromuscular disorders with heterogeneous genetic causes (NGS panel use)

Suspected neuromuscular disorders with heterogeneous genetic causes — studies support NGS panel use when phenotype is non-specific:

Indications: Individuals with suspected limb-girdle muscular dystrophy, congenital myopathies, metabolic myopathies (including Pompe), hereditary ataxia, or inherited peripheral neuropathies where clinical features are non-specific and multiple genes may explain the phenotype.

MotorPlex and targeted muscle panel studies demonstrate substantial diagnostic yields when clinical diagnosis is uncertain.

Rationale: NGS multi-gene panels can increase diagnostic yield, reduce time to diagnosis, and help differentiate treatable conditions (for example, Pompe disease) when preliminary biochemical or histologic testing is integrated into the diagnostic pathway.

Levesque, Lantern Project, and Savarese studies support combined enzymatic/genetic approaches for metabolic myopathies and myopathies.

Suspected IPN, HSP, CMD, LGMD or related myopathy (targeted NGS + CNV)

Documentation and Prior Testing Required

Structured eligibility nodes are used in the policy to capture clinical and documentation requirements that determine coverage. These top-level criteria guide whether testing meets the policy’s phenotype-driven and prior-testing-based approach to medical necessity.

When present, a documented family history consistent with hereditary inheritance should be included in the clinical record to guide gene selection and interpretation. However, the absence of a family history does not automatically preclude testing because de novo or variable-expression cases occur; family history is one element among phenotype, electrophysiology, and laboratory findings used to establish eligibility.

Document family history details when available (affected relatives, ages at onset, and pattern of inheritance). A compatible family history increases diagnostic yield and helps prioritize targeted testing, but testing may still be appropriate without it if clinical indicators support a hereditary etiology.

Eligibility requires clear documentation of clinical findings and prior diagnostic testing used to narrow the differential—examples include biochemical/metabolic testing (forearm exercise test, acylcarnitine mass spectrometry), EMG/nerve conduction studies, muscle biopsy results, and targeted genetic tests. These data should be recorded to justify progression to targeted NGS panels or broader genomic testing.

When relevant, documentation of prior targeted testing is required before pursuing broader assays. Examples include PMP22 duplication/deletion testing for Charcot–Marie–Tooth evaluation, GAA enzyme assays for suspected Pompe disease, and MLPA/CGH for suspected dystrophinopathy. The rationale for moving from targeted tests to panels, WES, or WGS should be included in the record.

Provide records of prior single-gene or copy-number testing (for example, candidate gene sequencing or CGH/MLPA results) when available. Evidence cited in the policy supports documenting prior testing to justify selection of panel size or escalation to exome/genome sequencing.

Provider Responsibilities and Prior Authorization

Prior Authorization

Prior Authorization, Prior Testing, and Test Selection

Prior targeted testing is generally recommended before ordering broad multi-gene NGS panels, whole exome sequencing (WES), whole genome sequencing (WGS), or dual genomic testing. Document prior targeted testing performed (for example: repeat or expanded single‑gene testing, copy‑number variant testing such as PMP22 duplication/deletion by MLPA or microarray, targeted CNV/CGH for dystrophin, or repeat expansion testing) and the clinical rationale for proceeding to a broader test. Failure to perform or document appropriate prior targeted metabolic, enzymatic, or CNV testing when indicated may affect coverage.

Prior authorization may be required when selecting broad NGS panels, WES/WGS, or reflex dual genomic approaches — check payer requirements before ordering.
If a broad panel is selected, document why a narrower/targeted panel or single‑gene test was not sufficient (e.g., atypical phenotype, prior negative targeted testing, complex or overlapping phenotype).
When hereditary peripheral neuropathy is suspected, rule out common copy‑number/repeat causes (e.g., PMP22 duplication/deletion) before or in parallel with broader testing per guideline-recommended stepwise approach.

Not Medically Necessary / Not Covered

Broad genetic testing performed without an appropriate diagnostic workup (clinical, biochemical, imaging, or electrophysiologic) may be unsupported and could be considered not medically necessary. The policy supports a diagnostic pathway that uses available clinical investigations to inform targeted genetic testing selection.

Routine genetic testing for individuals with cryptogenic polyneuropathy who lack a classical hereditary phenotype is considered not covered under this policy. The AAN/AANEM guidance cited in the policy states there is insufficient evidence to support routine testing in these cases.

The policy does not support use of limited mtDNA mutation panels alone when full mtDNA genome NGS is indicated. The Mitochondrial Medicine Society recommends NGS of the mtDNA genome for suspected mitochondrial disease and tissue-based testing when blood is negative but clinical suspicion persists.

Multi-gene comprehensive neuromuscular disease panels that combine testing for multiple distinct conditions (for example, muscular dystrophy and mitochondrial disease on the same panel) are listed as not medically necessary in this policy update and therefore are not covered as standard testing options.

Definitions and Background

Neuromuscular disorders encompass a genetically heterogeneous group of conditions including myopathies, metabolic myopathies (glycogen storage diseases and fatty acid oxidation disorders), mitochondrial myopathies, hereditary ataxias, and inherited peripheral neuropathies. Because many of these disorders have overlapping clinical features, targeted NGS panels—used in conjunction with biochemical, enzymatic, electrophysiologic, and imaging studies—can improve diagnostic yield and guide management decisions such as enzyme replacement therapy or cardiac surveillance.

Metabolic myopathies definition

DefinitionGenetic disorders in which muscle metabolic processes are disrupted, causing muscle weakness, exercise intolerance, or muscle pain; includes glycogen-storage diseases (GSD), disorders of fatty acid oxidation, and mitochondrial myopathies.

Common categoriesGlycogen‑storage diseases (e.g., Pompe), fatty acid oxidation disorders, and mitochondrial myopathies.

Typical clinical featuresExercise intolerance, muscle weakness, cramps or pain, and symptoms precipitated by fasting, illness, or endurance activity.

Diagnostic considerationsBiochemical/enzymatic testing (eg, GAA assay for Pompe) and targeted genetic testing guided by phenotype are often required prior to broader genomic testing.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neuromuscular Disorders (for Nebraska Only)

Policy CodePolicy CSIGSNE.D

Change TypeCoverage rationale addedsupporting sections revised

Effective DateOct 1, 2024

Next Review Date

Key ActionDocument prior targeted testing and clinical findings when requesting broader NGS panels or WES/WGS to support medical necessity.

SourceLink

On This Page

Muscle biopsy can guide gene selection and identify metabolic or mitochondrial features.

mtDNA testing methodology and tissue selection: Use massively parallel sequencing (NGS) of the mtDNA genome rather than limited mutation panels; if blood testing is negative but clinical suspicion remains, test an alternate tissue (e.g., muscle or urine) to detect tissue-specific heteroplasmy and perform mtDNA copy-number testing when depletion is suspected.

Mitochondrial Medicine Society recommends mtDNA genome NGS and tissue selection due to heteroplasmy.

Reflex to WES/WGS or dual genomic testing: If targeted panels and tissue testing are nondiagnostic, consider whole-exome sequencing, whole-genome sequencing, or dual genomic testing (nuclear + mitochondrial) depending on clinical context, documentation of prior testing, and laboratory coverage characteristics.

Studies and specialty guidance support reflex to broader genomic testing when panels are nondiagnostic.

Policy revision clarifies multi-condition panels are unproven and may be denied.

Suspected IPN, HSP, CMD, LGMD or related myopathy where clinical phenotype or diagnostic tests support hereditary etiology — targeted panels with CNV analysis supported:

Clinical prerequisites: Clinical phenotype consistent with inherited peripheral neuropathy, hereditary spastic paraplegia, congenital muscular dystrophy, limb-girdle muscular dystrophy, or related myopathy, and documentation of family history or diagnostic test results that support a hereditary etiology (eg, nerve conduction studies, biopsy findings).

Antoniadi, O'Grady, and Winckler studies demonstrate utility of targeted panels in these settings.

Test modality: Targeted multi-gene NGS panels that include CNV analysis (and MLPA/CGH when indicated) are appropriate as first-line or early testing in these indications due to higher diagnostic yield compared with sequential single-gene testing.

IPN and CMD cohort studies show diagnostic rates supporting panel-based strategies.

Individuals with limb girdle, humeroperoneal, distal, or combined weakness (inherited myopathy)

Individuals with limb girdle, humeroperoneal, distal, or proximal+distal weakness where phenotype, biopsy, EMG, CK, or family history suggests inherited muscular dystrophy or myopathy:

Clinical evaluation: Document pattern of weakness, relevant muscle biopsy findings (eg, myofibrillar features, sarcolemmal protein abnormalities), EMG results, CK levels, and family history to inform targeted genetic testing selection.

AAN/AANEM recommendations emphasize phenotype- and biopsy-directed testing to prioritize genes or small panels.

Testing pathway: If a specific clinical or biopsy phenotype implicates particular genes, pursue single-gene or small-panel testing first; if phenotype is non-specific or initial testing is nondiagnostic, use targeted NGS panels (with CNV testing) as next step; consider reflex to WES/WGS when panels are nondiagnostic.

Cohort studies of LGMD/MFM report higher yields for targeted panels and support this stepwise approach.

Suspected mitochondrial disease — dual genomic testing and tissue considerations

Individuals with suspected mitochondrial disease based on clinical, biochemical, or biopsy findings — dual genomic testing and tissue selection considerations:

Clinical and laboratory indicators: Suspected mitochondrial syndromes (eg, CPEO, KSS, MERRF, MELAS, Leigh, NARP) based on clinical features, lactic acidosis, muscle biopsy (ragged red fibers), or multisystem involvement warrant mitochondrial-focused genetic evaluation.

Mitochondrial phenotypes are heterogeneous and may require targeted tissue testing due to heteroplasmy.

Genomic testing strategy: Dual genomic testing (nuclear gene panel plus mtDNA genome NGS) can be appropriate in multisystem or pediatric cases; tissue selection (muscle, urine) matters because heteroplasmy levels vary by tissue and blood testing may be insufficient.

Parikh and MMS guidance support tissue-based mtDNA testing and dual genomic approaches when indicated.

Testing for suspected primary mitochondrial disease and other inherited NMDs

Testing for suspected primary mitochondrial disease and other inherited NMDs using appropriate targeted NGS panels or WES when indicated:

Panel preference and coverage: When nuclear gene testing is pursued for likely primary mitochondrial disease, prefer NGS panels that provide comprehensive coverage of known mitochondrial disease genes rather than single-gene testing; if such panels are nondiagnostic, consider WES.

Mitochondrial Medicine Society recommends NGS panels with complete gene coverage and avoidance of single-gene testing due to phenotypic overlap.

mtDNA testing methodology: Use mtDNA genome NGS (massively parallel sequencing) rather than limited mutation panels; perform mtDNA copy-number testing when depletion is suspected and consider alternate tissue testing for heteroplasmy assessment.

MMS strongly prefers mtDNA genome NGS and tissue-specific testing for accurate detection of pathogenic variants.

Repeat prior-testing documentation expectations are emphasized: include prior sequencing, CNV testing, and results of any targeted assays so the necessity of broader testing can be evaluated against prior negative or inconclusive findings.

Additional structured eligibility elements may include documentation of specialist involvement (neuromuscular or clinical genetics), evidence of prior genetic counseling, and notation of tissue source for mitochondrial testing when heteroplasmy or mtDNA depletion is a concern.

Documentation Required

Phenotype Requirement and Clinical Justification

A clinical phenotype that supports genetic testing must be documented. Testing is not routinely supported for cryptogenic polyneuropathy without a classical hereditary phenotype. Provide documentation of the presenting phenotype, suspected inheritance pattern, and key electrodiagnostic features that narrow the differential. Include family history and whether features are consistent with an autosomal dominant, autosomal recessive, X‑linked, de novo, or mitochondrial inheritance pattern.

For distal symmetric polyneuropathy (DSP), initial testing should focus on the most common abnormalities (e.g., PMP22 duplication/HNPP deletion, GJB1, MFN2) guided by family history and electrodiagnostic testing.
If phenotype is non‑specific, explain why targeted testing would be low yield and why broader testing is justified (e.g., prior targeted testing negative, progressive childhood onset, consanguinity).

Documentation Required

Required Clinical and Laboratory Documentation

Provide focused clinical and laboratory documentation to justify the genetic test ordered. Document findings that help narrow the differential (pattern of weakness, distribution, age of onset, progression), relevant laboratory or biochemical results (CK, enzymatic assays such as GAA activity for Pompe, lactic acid/pyruvate, metabolic testing), electrodiagnostic testing (EMG/NCS) results, and muscle biopsy findings when available. For mitochondrial disease, include biochemical respiratory chain testing and prior mtDNA testing results when applicable.

Include results of prior biochemical/metabolic testing (e.g., GAA enzyme assay for Pompe) when available — omission may affect coverage determination.
For neuromuscular disorders, document CK level, EMG patterns, cardiopulmonary involvement, and any biopsy findings (e.g., ragged red fibers, central cores, dystrophin staining abnormalities).

Documentation Required

Laboratory, Specimen, and mtDNA Methodology Requirements

Laboratory and specimen documentation must be provided. Use CLIA‑certified laboratories and specify tissue source(s) submitted. For suspected mitochondrial disease, document mtDNA testing methodology and heteroplasmy considerations: massively parallel NGS of the entire mtDNA genome is the preferred method, and if blood testing is negative but clinical suspicion remains, testing of an alternate tissue (e.g., muscle or urine) is recommended. Consider mtDNA copy‑number (depletion) testing via qPCR when a tissue biopsy is obtained.

State the CLIA status of the performing laboratory and the exact specimen type submitted (blood, muscle, urine).
For mtDNA testing, indicate whether full mtDNA genome NGS was performed and report heteroplasmy levels; if only targeted mutation testing was done, state rationale — limited panels are discouraged for suspected mitochondrial disease.

Step Therapy

Recommended Stepwise Testing and Reflex Strategy

Follow a recommended stepwise, algorithmic testing approach unless clear clinical justification for bypassing steps is provided. High‑yield, disease‑specific tests (CNV testing and repeat‑expansion testing where indicated) should generally be performed first, followed by targeted multi‑gene NGS panels focused on the relevant phenotype, and then reflex to WES/WGS or broader exome panels for unresolved cases. This approach is endorsed by multiple specialty guidelines and diagnostic studies.

Example sequence for inherited peripheral neuropathy: first-tier CNV/repeat testing (PMP22 duplication/deletion), targeted gene panel guided by phenotype and family history, then WES if panel negative and clinical suspicion persists.
For mitochondrial disease: preferred pathway is targeted nuclear gene panels with comprehensive mtDNA testing, with reflex to WES when panel and mtDNA testing are unrevealing.

Prior Authorization

Prior Testing, Rationale for Panel Size, and Reflex to WES/WGS

Document prior testing and the rationale for panel size versus exome sequencing. If prior targeted testing was negative, list which tests were performed, their dates and results, and explain why a larger panel or exome is necessary (e.g., atypical presentation, prior negative targeted NGS panels, family segregation data, consanguinity, or the need to evaluate genes not covered by smaller panels).

When ordering reflex strategies (targeted panel with reflex to WES/WGS), specify the triggering criteria for reflex (e.g., negative panel with persistent high clinical suspicion, candidate gene not included on panel).
If WES/WGS is requested initially, provide documentation of why a targeted panel would be insufficient and include supporting clinical details and prior test results.

Inherited peripheral neuropathies (IPN) definition

DefinitionA heterogeneous group of inherited disorders caused by variants in over 90 genes, characterized by progressive distal weakness, muscle atrophy, and sensory loss; major subtypes include Charcot‑Marie‑Tooth (CMT), hereditary sensory and autonomic neuropathy (HSAN), hereditary motor neuropathy (HMN), and hereditary neuropathy with liability to pressure palsy (HNPP).

EpidemiologyCMT affects ~16 per 100,000 individuals; overall IPN prevalence estimates vary (examples noted in literature).

Clinical classificationElectrodiagnostic testing classifies CMT as demyelinating or axonal; one gene can cause multiple phenotypes and all inheritance patterns have been reported.

Testing implicationTargeted NGS panels are an attractive option due to the large number of genes implicated and cost limitations of sequential Sanger sequencing.

Hereditary Spastic Paraplegias (HSP) definition

DefinitionA group of genetic diseases marked by slowly progressive, symmetrical spastic paraplegia of the legs due to distal axonal degeneration; classified as 'pure' or 'complex' with over 70 genes identified.

Typical presentationProgressive spasticity of the lower limbs, often beginning in childhood or young adulthood; minor sensory abnormalities and urinary involvement are common; arm involvement is minimal if present.

InheritanceBoth autosomal dominant and autosomal recessive forms occur; complex forms more common in populations with consanguinity.

Congenital Muscular Dystrophies (CMD) definition

DefinitionDisorders of muscle weakness and hypotonia that manifest in the first two years of life; major categories include collagenopathies (eg, COL6A1/2/3), merosinopathies (LAMA2), and dystroglycanopathies.

Clinical featuresEarly-onset weakness and hypotonia, often with elevated serum creatine kinase (CK) and muscle biopsy abnormalities (necrosis, regenerating fibers, variable fiber size, increased connective tissue).

Associated findingsMany CMDs have variable brain and ocular involvement; phenotypic overlap exists among dystroglycanopathies and other CMD subtypes.

Heteroplasmy definition — variable mtDNA copies within cells

DefinitionPresence of multiple copies of normal and abnormal mitochondrial DNA (mtDNA) within a cell, producing variable phenotypic expression and complicating DNA testing and interpretation.

Impact on testingHeteroplasmy leads to tissue-specific levels of mutant mtDNA; NGS improves detection sensitivity (can detect low‑level heteroplasmy in blood depending on methodology and tissue).

Clinical relevanceDegree of heteroplasmy helps explain the wide range of clinical severity and may necessitate testing of non‑blood tissues (eg, muscle or urine).

mtDNA genome NGS — definition and MMS preference

DefinitionMassively parallel sequencing (next‑generation sequencing) of the mitochondrial genome (mtDNA); recommended by the Mitochondrial Medicine Society as the preferred methodology for mtDNA testing.

Policy implicationNGS of the full mtDNA genome should be performed instead of testing for a limited number of pathogenic mutations when mitochondrial disease is suspected.

Tissue considerationsIf blood testing is negative but clinical suspicion remains, mtDNA should be assessed in another tissue (eg, muscle or urine) to avoid missing tissue‑specific mutations or low heteroplasmy in blood.

mtDNA proliferation — definition/context

DefinitionAn observed increase in mitochondrial content or appearance (mtDNA proliferation) that is a nonspecific compensatory finding seen in primary mitochondrial disease, secondary mitochondrial dysfunction, myopathy, hypotonia, and after intense exercise.

Interpretation noteBecause mtDNA proliferation is nonspecific, it should be interpreted cautiously and in the context of clinical, biochemical, and genetic data.

Diagnostic usemtDNA proliferation alone does not confirm primary mitochondrial disease and additional testing (eg, NGS mtDNA, nuclear gene sequencing, biochemical assays) may be needed.

mtDNA copy number testing (mtDNA depletion analysis) — definition

DefinitionReal‑time quantitative PCR testing to assess mtDNA content in tissues (mtDNA copy number) used for mtDNA depletion analysis.

Testing guidanceMMS recommends strongly considering tissue‑based mtDNA copy number testing because mtDNA depletion may not be detected in blood.

Specimen noteWhen a tissue specimen is obtained for mitochondrial studies, include mtDNA copy number testing to evaluate for depletion; blood may be insufficient.